These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. Zheng MK; Shih DQ; Chen GC World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759 [TBL] [Abstract][Full Text] [Related]
25. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687 [TBL] [Abstract][Full Text] [Related]
27. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System? Gonczi L; Ilias A; Kurti Z; Lakatos PL Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504 [TBL] [Abstract][Full Text] [Related]
28. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. Bhat S; Limdi JK; Cross RK; Farraye FA Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024 [TBL] [Abstract][Full Text] [Related]
29. Biosimilars in Inflammatory Bowel Disease. Buchner AM; Schneider Y; Lichtenstein GR Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013 [TBL] [Abstract][Full Text] [Related]
30. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387 [TBL] [Abstract][Full Text] [Related]
31. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. Crosby M; Tadrous M; Gomes T Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249 [TBL] [Abstract][Full Text] [Related]
32. Biosimilars in inflammatory bowel disease: A review of post-marketing experience. Deiana S; Gabbani T; Annese V World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193 [TBL] [Abstract][Full Text] [Related]
33. Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future. Berns M; Hommes DW Expert Opin Investig Drugs; 2016; 25(2):129-43. PubMed ID: 26616476 [TBL] [Abstract][Full Text] [Related]
34. Biosimilars in the therapy of inflammatory bowel diseases. Hlavaty T; Letkovsky J Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561 [TBL] [Abstract][Full Text] [Related]
35. Biosimilars: in support of extrapolation of indications. Ebbers HC J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005 [TBL] [Abstract][Full Text] [Related]
36. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Jahnsen J; Detlie TE; Vatn S; Ricanek P Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534 [TBL] [Abstract][Full Text] [Related]
37. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037 [TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Behm BW; Bickston SJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120 [TBL] [Abstract][Full Text] [Related]